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Abstract: Spasticity is the most common motor disturbance in cerebral palsy (CP). Lockdown in the COVID-19 outbreak has profoundly
changed daily routines, and similarly caused the suspension of spasticity treatment plans. Besides, the delay in botulinum toxin (BoNT)
injection, which is important in the management of focal spasticity, led to some problems in children. This consensus report includes
BoNT injection recommendations in the management of spasticity during the COVID-19 pandemic in children with CP. In order to
develop the consensus report, physical medicine and rehabilitation (PMR) specialists experienced in the field of pediatric rehabilitation
and BoNT injections were invited by Pediatric Rehabilitation Association. Items were prepared and adapted to the Delphi technique
by PMR specialists. Then they were asked to the physicians experienced in BoNT injections (PMR specialist, pediatric orthopedists,
and pediatric neurologists) or COVID-19 (pediatric infectious disease, adult infectious disease). In conclusion, the experts agree that
conservative management approaches for spasticity may be the initial steps before BoNT injections. BoNT injections can be administered
to children with CP with appropriate indications and with necessary precautions during the pandemic.
Key words: Botulinum toxin, cerebral palsy, COVID-19, pandemic, spasticity

1. Introduction
Spasticity affects up to 80% of children with cerebral
palsy (CP) [1]. Management of spasticity is critical,

and postponing might result in complications such
as contractures, pain, skin breakdown, or functional
disability [2]. On the other hand, antispasticity treatments
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(rehabilitation, oral medications, botulinum toxin
(BoNT), intrathecal baclofen pump) require a detailed
physical examination and close monitoring for appropriate
treatment selection [1,3]. Close follow-up is also vital in
BoNT injections, one of the first-line treatments in focal
spasticity; attention must be paid to the selection of the
correct muscle and the need for repeated injections within
3–6 months [4]. Lockdown in COVID-19 outbreak has
profoundly changed daily routines, and similarly caused
the suspension of spasticity treatment plans [3,5].
In pediatric age, the immune system is not mature,
and it makes the pediatric patients susceptible to upper
respiratory tract infections. Although COVID-19 is also
a kind of upper respiratory tract infection at least at the
beginning of the disease, the lower prevalence of COVID-19
in children is confusing [6]. Symptoms are often mild in
children. They can be asymptomatic or present with most
commonly fever and cough (42%). Upper respiratory
tract symptoms such as nasal congestion or headache [7]
or gastrointestinal symptoms such as diarrhea, vomiting,
or abdominal distension can accompany [8]. Fatigue,
sore throat, sputum, upper airway infections, pharyngeal
erythema, tachycardia, tachypnea, pneumonia, respiratory
distress, and hypoxemia are other manifestations [9].
Children with underlying diseases such as congenital
heart and lung disease, chronic heart and kidney disease,
hereditary metabolic, immunodeficiency diseases,
malnutrition, and malignancy are likely to become severe
cases for COVID-19 infection [10]. Among 48 critically
ill children with COVID-19, more than 80% had major
chronic diseases. Dependency on technological support,
including tracheostomy, developmental delay, and
seizures were other common comorbid conditions [11].
In a pediatric intensive and high-dependency care unit in
France, 7 out of 27 patients had underlying neurological
disease [12]. Among 130 children with confirmed
COVID-19 diagnosis from 28 centers in Italy, there was
one case with CP [13]. Although there is scarcely any data
on whether children with CP had a higher prevalence of
COVID-19, intellectual, and communication problems
might complicate the interpretation of the symptoms in
CP. Drooling, finger sucking, rolling over, or crawling
habits might increase the possibility of viral transmission.
On the other hand, mobility restrictions and dependency
to parents might lead children with CP to obey the rules of
“stay at home” and “social distancing” more than the ablebodied children.
Many rehabilitation centers and specialized education
centers reduced their services to prevent the spread
of the infection and to protect the patients and their
caregivers [14]. Among 68 children receiving conventional
rehabilitation for pediatric or perinatal stroke before
the COVID-19 pandemic in Italy, only 5.9% continued
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conventional rehabilitation. Telerehabilitation and
indirect remote supervision modalities were used in
23.5% and 42.6% of children, respectively. The rest did not
receive any kind of rehabilitation [15]. Home programs
had beneficial outcomes on the functions of the children
and parent satisfaction [16]. A family-centered approach
gained more importance in pediatric rehabilitation during
this outbreak.
The treatment approach to CP-related spastic
movement disorders should cover all conservative and
surgical strategies and requires a regular interdisciplinary
multimodal team approach. The success of BoNT depends
on the adjunctive use of physiotherapy and splinting or
casting. Delay of this effective treatment strategy that
relieves pain, enhances the effects of physiotherapy,
improves performance in activities of daily living, and
decreases the burden of caregivers [17] caused some
problems in the children during the pandemic.
On the other hand, possible systemic adverse events
due to systemic diffusion of the BoNT such as generalized
weakness, flu-like syndrome, fatigue, asthenia, dysphagia,
and even death might complicate the symptoms of
COVID-19 [18–20]. The onset of the flu-like syndrome
after injection is sudden. Fever is temporary in contrast
to that of COVID-19 [19]. These adverse events are
more common in patients with gross motor functional
classification system (GMFCS) levels IV and V [18].
Respiratory complication associated with anesthesia was
another concern whether it suppresses the immunity
against COVID-19 [18,21,22].
This consensus was planned to provide a guide
especially for the physicians who apply BoNT injection to
the children with CP. This report aims to answer certain
questions related to BoNT injection; I. Is botulinum
toxin injection safe during the COVID-19 pandemic in
the pediatric population? II. Is there any difference in the
selection criteria for BoNT injection during the pandemic?
III. Which precautions should be taken for BoNT injection
during the pandemic?
2. Methods
The Delphi technique was used for this consensus. It is a
method used to publish recommendation or guidelines
with consensus on a subject which there is not enough
evidence and which the experts cannot meet simultaneously
[23]. Both COGS checklist [24] and CREDES checklist,
which have recommendations for Delphi methods, were
reviewed and used for this study [25]. In accordance with
these guidelines; as the first step, physical medicine and
rehabilitation (PMR) specialists experienced in the field
of pediatric rehabilitation and BoNT injections were
invited by Pediatric Rehabilitation Association in Turkey,
to develop a consensus report about administering BoNT
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injections in children with CP during the COVID-19
pandemic. Twenty physiatrists were divided into four
groups of 5 physiatrists and searched the literature under
four headings. These four headings are:
1) COVID-19 in children and children with disabilities,
2) Evaluation of BoNT in terms of COVID-19 risk,
3) Evaluation of BoNTinjection methods in terms of
COVID-19 risk,
4) Necessary precautions during BoNT injections.
A literature search was conducted in PubMed,
CINAHL, Google Scholar, Cochrane, and related online
databases. Metaanalyses, systematic reviews, randomized
studies, guidelines and statements, web sites of World
Health Organization (WHO), and the Turkish Ministry
of Health were investigated about BoNT and injection
methods including anesthesia, ultrasound (US), and
electromyography (EMG).The language of the literature
search was English. Key words were “COVID 19 + Cerebral
Palsy + Botulinum toxin”, “COVID 19 + Botulinum toxin”,
“EMG + COVID 19 + Cerebral Palsy”, “Ultrasound
+ COVID-19”, “Anesthesia + COVID-19”,“Pediatric
Anesthesia + COVID-19”,“Pulmonary + COVID-19 +
Child”.
After the participants reviewed the literature and
prepared items according to the patient, intervention,
comparison, outcome “PICO” strategy [26], the items
prepared were reviewed by four authors (NÇ, EYY, EKS,
ÖÖT) separately, and relevant items were arranged in
terms of language integrity and comprehensibility. A pilot
test of the survey was administered to 5 physicians who
did not participate in this study. Then the final version of
the items adapted to the Delphi technique was approved
by four authors. The final version which included 67 items
was conveyed to PMR specialists (n = 34), orthopedic
surgeons (n = 7), pediatric neurologists (n = 2) experienced
in BoNT injection, anesthesiologists (n = 7), infectious
disease specialists (n =5 ), and pediatric infectious disease
specialists (n = 5) via the Qualtrics Program. For each
item, the participants were asked to mark as “Agree”,
“Disagree”, or “No idea/Uncertain” in the light of the
existing data and their experiences. Item agreement was
analyzed. Agreements more than 70% of the participants
were accepted as strong, and agreements between 65% and
70% were accepted as moderate. Flow diagram of the study
was shown in Figure.
3. Results
Sixty experts accepted to answer Delphi questions. There
were 34 PMR specialists, seven orthopedic surgeons, two
pediatric neurologists, seven anesthesiologists, and five
infectious and five pediatric infectious disease specialists.
In the pandemic, after lockdown was over, 13
physicians (22%) injected BoNT to the adult patients

and 13 physicians (22%) to the pediatric patients. No
complications were observed. In this consensus report, 25
items reached a strong agreement and were accepted as a
strong recommendation, and two items had a moderate
agreement.
3.1. Management strategies in spasticity and appropriate
patient selection for BoNT injection
1. During COVID-19 pandemic, the stress and anxiety
of children with disabilities and their families and closure
of the rehabilitation centers may increase the spasticity of
the children.
2. Rehabilitation approaches at home are effective in the
development of motor functions. Other treatments instead
of BoNT injections are more appropriate for children with
CP including those with severe comorbidities such as
dysphagia, frequent lung infections, having percutaneous
endoscopic gastrostomy (PEG), or nasogastric tube. Before
BoNT injection, family-oriented rehabilitation and games
and telerehabilitation may be recommended.
3. BoNT injections can be administered in children
with the appropriate indications during the pandemic with
necessary precautions. BoNT can be postponed if there is
no deterioration in functional status.
4. Telemedicine evaluation reduces the risk of COVID
transmission. However, it may not be appropriate to decide
for BoNT injections for every child via telemedicine alone,
without face-to-face examination.
3.2. Evaluation before BoNT Injection
5. COVID-19 symptoms and contact history should
be questioned together with other viral and bacterial
infections before the injection day and should be repeated
on the injection day. A separate inquiry form should also
be filled for the family/caregiver.
6. Particular attention should be paid for children with
intellectual and communication problems in questioning
their families regarding the symptoms of their children.
7. The history of an adverse event related to previous
BoNT injection should be questioned.
8. Children with GMFCS IV and V are at increased risk
for more severe COVID-19 if infected.
9. Parents should be informed about the risk of
COVID-19, and their consent should be obtained before
the procedure.
10. Real-time reverse transcription-polymerase chain
reaction (RT-PCR) test should be ordered if there is
clinical suspicion of COVID-19. Children with a history
of COVID-19 infection or 2-week quarantine are advised
to be consulted with an infectious disease specialist.
11. RT-PCR might be ordered before BoNT injections
that will be performed in the operating room under
sedation or general anesthesia (moderate agreement).
12. There is no need to repeat the RT-PCR test in a child
who recovered from COVID-19 and had no symptoms
left, with negative RT-PCR at least twice.
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To define the questions regarding
saf e BoNT injections for the children with
CP

PMR experts in pediatric rehabilitation and/or
BoNT injection were invited

20 PMR experts accepted to participate
4 groups studied in 4 main topics
(5 PMR experts in each groups)

Items were developed
based on experts’ opinions

Questionnaire was sent to experts

Questionnaire responses were analyzed

Agreement ≥70% of experts

A strongly
agreed consensus
item

Agreement 65-69% of experts

A mildly agreed
consensus item

Round 1
Literature review

Round 2
67 items were prepared

Round 3
Sent to 60 experts

Round 3
60 experts answered

Agreement <65 % of experts

Not reported as a
consensus item

Report as mild
agreed consensus
(2 items)

Figure. Flow diagram of the consensus and the Delphi method.
(BoNT: Botulinumtoxin, CP: cerebral palsy, PMR: physical medicine and rehabilitation)

3.3. BoNT injection procedure
13. Going to the hospital and receiving anesthesia may
increase the risk of COVID-19 infection in the children
with CP.
14. Screening of body temperature at the entrance of
the hospital should be performed.
15. Necessary precautions should be taken to reduce
the patient’s waiting time and the number of accompanying
persons.
16. For BoNT injections, sedoanalgesia or local
anesthetic creams could be preferred in appropriate
patients including children with severe comorbidities such
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as frequent lung infections or dysphagia, especially those
with PEG or nasogastric tube (moderate agreement).
17. In injections under general anesthesia; complete
blood count, C-reactive protein, and biochemistry might
be ordered before the procedure.
18. Computed tomography (CT) should be requested
only in suspected cases by consulting pediatrician/
pediatric infectious disease specialists.
19. The risk of COVID-19 transmission may increase
as the duration of the injection procedure gets longer. To
shorten the BoNT procedure, selection of the muscles and
doses should be made before entering the injection room.
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Electroneuromyography (EMG) and ultrasonography
(US) application time should be kept as short as possible.
20. Proper disinfection of EMG cables and stimulators
or the US probe and cable should be performed before and
after each patient. EMG needles should be disposable.
21. Medical staff should use appropriate personal
protective equipment during examination and injection.
Medical staff may change their surgical masks before each
patient if needed.
22. In the injection room, the number of medical staff
or parent/caregiver should not be more than adequate.
23. It is not recommended to use a mask for children
under 2 years old, those who have difficulty breathing, and
those who cannot remove the mask without help.
24. Before the injection; body temperature, heart rate,
oxygen saturation, and the frequency of breathing should
be measured.
25. Hourly follow-up is sufficient for children with CP
after BoNT injection. Hospitalization for monitoring after
the injection may increase the risk of viral transmission.
26. In the days following BoNT injection, the patient
should be followed closely for COVID-19 symptoms.
27. Fever following BoNT injection may be confused
with a symptom of COVID-19. RT-PCR test might be
requested in a patient with fever and other symptoms that
started 2-3 days after BoNT injection.
4. Discussion
This consensus report aims to define recommendations
for safe BoNT injection applications both for the children
with CP and healthcare workers during the pandemic.
The experts agree that BoNT injections can be postponed
if there is no deterioration of functional status and other
antispasticity strategies may be more appropriate before
BoNT injections, especially in children with severe
comorbidities. There existed a strong agreement for the
administration of BoNT injections to appropriate children
with CP after taking necessary precautions during the
pandemic. Telemedicine evaluation and telerehabilitation
are options that can be benefited to reduce the risk of
COVID-19 transmission.
Before injection, COVID-19 symptoms and contact
history should be carefully questioned. There is no need to
order the RT-PCR test before injection routinely, and the
test should be requested only in the suspected cases. The
experts agreed that it is crucial to inform the parents about
the risk of COVID-19 and obtain their consent before the
procedure. The majority of the respondents recommended
using sedoanalgesia or local anesthetic creams rather
than general anesthesia during injections for eligible
cases, including severe comorbidities. On the other hand,
premedication may be necessary before general anesthesia
to reduce airborne and droplet transmission, especially in

anxious patients crying and coughing [27].
The current consensus suggests determining the doses
and muscles before entering the injection room to shorten
the duration of BoNT procedure. It is recommended
not to use high doses, especially for children in GMFCS
levels IV and V with higher risks for aspiration and
respiratory complications [28]. Dysphagia, history of
aspiration pneumonia, epilepsy, or gastrostomy has been
associated with an increased risk of adverse events [29,30].
The number of medical staff should not be more than
adequate similar to the literature on anesthesia procedures
for pediatric patients [31]. This consensus stated that
medical staff is recommended to use appropriate personal
protective equipment during examination and injection
and change mask for each patient if needed and proper
disinfection of cable and stimulators for EMG probe and
cable for the US is recommended before each patient.
Patients and caregivers should wear face masks except
for young children under 2 years of age, children with
difficulty breathing, or those who are unable to remove the
mask without help similar to Center for Disease Control
and Prevention [32].
Similarly, Canadian Spasticity COVID-19 Task Force
recommends cleaning all points contacted with the
patients, including EMG equipment with isopropyl alcohol
or a hard-surface disinfectant [33]. Some physicians prefer
the portable EMG equipment instead of standard EMG
machines because the disinfection of the smaller devices
could be easier. The room and the neuro-diagnostic
devices could be disinfected by ultraviolet-C light [34].
In another guide, US was recommended for BoNT
injection during this outbreak [35]. Anesthesiologists
advise wrapping US device, its probe and cable with a
disposable plastic sheath [36,37]. Allam et al. suggested
that the probe and the entire device should be cleaned
with disinfectant wipes. The sterile disposable gel should
be used for the US-guided intervention. Before each USguided intervention, the medical staff should change N95/
FFP2/KN95 or wear a surgical mask on it [35]. However,
in our country, the Turkish Ministry of Health Guidelines
recommend using only surgical mask in the procedures
that do not produce aerosol1.
In the literature, there is no evidence-based data
regarding the interaction of BoNT with COVID-19. In a
recent paper, BoNT was proposed as a treatment against
COVID-19; this hypothesis should be interpreted very
carefully since it is not evidence-based [38]. More evidence
is needed to infer a definitive decision. Future studies
1
COVID-19 (sars-cov-2 enfeksiyonu). Çocuk hasta yönetimi ve
tedavi. Bilimsel danışma kurulu çalışması [Online] (in Turkish).
Web site: https://covid19.saglik.gov.tr/TR-66393/covid-19salgin-yonetimi-ve-calisma-rehberi.html [Accessed 03 June
2020]
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that follow the adverse events following BoNT injections
during the pandemic would be valuable.
The RT-PCR test performed with nasopharyngeal and
throat swabs can only be reliable in the 1st week of the
disease [39]. Wang et al. reported that the sensitivity for
nasal and pharyngeal swab is 63% and 32%, respectively,
in the confirmed patients [40]. This consensus strongly
suggested the RT-PCR test only in the clinical suspicion
of COVID-19. On the other hand, there was moderate
agreement to order the RT-PCR test before BoNT injections
planned in the operating room under either sedation or
anesthesia. Since there is no specific pathognomonic
laboratory test for COVID-19 [41,42], this consensus did
not recommend to order routine laboratory tests. Before
general anesthesia, complete blood count and C-reactive
protein are recommended. As plain chest radiography is
not a specific imaging modality to diagnose or rule out
COVID-19, chest CT is the recommended modality in
suspected cases with consulting a pediatrician or pediatric
infectious disease specialists [42].
This consensus has some limitations. COVID-19 is a
novel virus and there is no definitive treatment yet. It may

undergo mutation and become more or less contagious.
In this case, our recommendations might need some
revisions and updates. Another limitation is that there
are no evidence-based studies regarding BoNT injections
during the pandemic. Therefore, consensus and the Delphi
method was used. Agreement over 70% was considered a
strong recommendation and agreement of 65–69% as a
mild recommendation. Although in some studies, 80%
agreement was accepted as a strong recommendation,
agreement rate was mostly reported as 70% in the literature
similar to our consensus report [25].
In conclusion, BoNT injections can be administered
in children with CP without COVID-19 symptoms or
contact history following appropriate personal protective
equipment and disinfection rules.
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